BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

FDA OKs Novartis AG (NVS)'s Afinitor Disperz for Child Brain Tumors


8/30/2012 7:29:22 AM

The Food and Drug Administration on Wednesday cleared a new formulation of Novartis' drug Afinitor to treat very young patients with brain tumors caused by a rare genetic disorder. The new formulation, Afinitor Disperz, was cleared to treat children as young as 1 year old who have inoperable tumors caused by tuberous sclerosis. Tuberous sclerosis causes tumors in the brain, eyes, lungs, liver and other organs, leading to learning disabilities, seizures and other problems. The tumors are not cancerous, but they can be fatal for patients who develop complications from tumor growth in the brain.

Read at CBS News
Read at PharmaBiz
Read at BusinessWeek
Read at Fox News
Read at Chicago Tribune

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->